A Smart + Strong Site
Subscribe to:
POZ magazine

Back to home » Treatment News » Top Stories

Most Popular Stories
Undetectable Viral Load Essentially Eliminates Transmission Risk in Straight Couples
FDA Approves New Single-Tablet HIV Regimen, Triumeq
Life Expectancy for Young People With HIV Is Nearly Normal
A 15-Year Jump in Life Expectancy for People With HIV
Scientists Devise Method of Snipping HIV From Immune Cells
Monkey HIV Vaccine Success Opens Door for Human Trials
HIV Combo Pill Less Toxic Thanks to New Form of Tenofovir
What's That Mean?
(just double-click it!)

If you don't understand one of the words in this article, just double-click it. A window will open with a definition from mondofacto's On-line Medical Dictionary. If the double-click feature doesn't work in your browser, you can enter the word below:

Most Popular Lessons
Aging & HIV
The HIV Life Cycle
Herpes Simplex Virus
Syphilis & Neurosyphilis
Treatments for Opportunistic Infections (OIs)
What is AIDS & HIV?
More News

Have medical or treatment news about HIV? Send press releases, news tips and other announcements to news@aidsmeds.com.

Click here for more news


January 3, 2011

Study Suggests Genetic Tests Could Predict HIV Drug Side Effects

A new study published in the January 15 issue of The Journal of Infectious Diseases suggests genetic testing might help predict whether a person will have side effects from some HIV drugs. This could allow people to avoid those drugs or at least take them with greater caution.

Previous studies have found that side effects can result in switching meds or discontinuing treatment in up to 45 percent of people starting HIV therapy for the first time. Thus far, however, researchers have found only one form of a gene (an allele) conclusively responsible for side effects: The HLA-B5701 allele, which causes people to have a hypersensitivity reaction to abacavir (found in Ziagen and Epzicom).

Other alleles have been linked to changes in drug blood levels or increased side effect risks for other HIV medications, but the influence of these alleles isn’t as predictable as that of the HLA-B5701 allele.

To determine whether other alleles might predict poor tolerability to drugs other than abacavir, Rubin Lubomirov, MD, PhD, from the University of Lausanne in Switzerland, and his colleagues analyzed data from 577 people enrolled in the Swiss HIV Cohort study. All of the people were starting HIV treatment for the first time.

The specific drugs they studied were abacavir, tenofovir (found in Viread, Truvada and Atripla), efavirenz (found in Sustiva and Atripla), Kaletra (which contains lopinavir and ritonavir) and Norvir (ritonavir)–boosted Reyataz (atazanavir).

Based on data linking alleles to side effects or drug level changes in previous studies, Lubomirov and his colleagues tested collected blood samples for 23 alleles in 15 genes.

The only significant genetic switch not included was the HLA-B5701 allele, because all people who took abacavir had already been tested for the allele and only those without it were allowed to take abacavir. With some drugs, the researchers looked at whether a single allele affected a drug’s tolerability, and with other drugs, Lubomirov’s team looked at the combined effect of several alleles.

The team did not directly assess the effect of certain alleles on specific side effects. They focused only on whether the alleles predicted dose adjustments or treatment discontinuation (though the most common reason for switching treatment in the study was side effects).

The team found that the presence of drug-specific alleles was highly predictive of a switch from efavirenz or Reyataz, but not for the other drugs.

Lubomirov’s group found that 71 percent of people with alleles in the CYP2B6 gene combined with secondary alleles to other genes had to switch off efavirenz or change the dose of the drug compared with only 28 percent of those who did not have the alleles. The risk was even higher in women.

Likewise, Lubomirov and his colleagues found that 62 percent of people with a double substitution in the UGT1A1 gene had to change or discontinue Reyataz, compared with 24 percent with a single substitution and only 15 percent with no substitutions.

“The study suggests that assessment of the genetic markers could lead to improved prescription of atazanavir and efavirenz,” the authors state. They conclude that “a prospective clinical trial should ideally formalize the analysis and provide the basis for measuring the cost effectiveness of this approach.”

Search: Allele, genes, HLA-B5701, CYP2B6, efavirenz, Sustiva, Atripla, abacavir, Ziagen, Epzicom, tenofovir, Viread, Truvada, Reyataz, atazanavir, Norvir, ritonavir, Kaletra, lopinavir, side effects, dose change, treatment discontinuation, Rubin Lubomirov

Scroll down to comment on this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The AIDSmeds team reviews all comments before they are posted. Please do not include ":" "@" "<" ">" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Show comments (0 total)

[Go to top]

Quick Links
About HIV and AIDS
The Cure
Lab Tests
Clinical Trials
HIV Meds
Starting Treatment
Switching Treatment
Drug Resistance
Side Effects
Hepatitis & HIV
Women & Children
Fact Sheets
Treatment News
Community Forums
Conference Coverage
Health Services Directory
POZ Magazine
AIDSmeds on Twitter

Conference Coverage

XX International AIDS Conference
(AIDS 2014)
Melbourne, Australia
July 20 - 25, 2014

21st Conference on Retroviruses and Opportunistic Infections
(CROI 2014)
Boston, MA
March 3 - 7, 2014

7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention
(IAS 2013)
Kuala Lumpur, Malaysia
June 30 - July 3, 2013

more conference coverage

[ about AIDSmeds | AIDSmeds advisory board | our staff | advertising policy | advertise/contact us]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.